As related studies further illustrated that the altered DNA damage response is a recurring mechanism at play in other ALS/FTD types, such as TDP-43 ALS [28, 29], our work points to HNRNPK and, in particular, its target RRM2 as novel focuses in developing new therapeutic strategies for ALS. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.